Lipid-modifying effects of rosuvastatin in postmenopausal women with hypercholesterolemia who are receiving hormone replacement therapy*
| Autor: | Evan A. Stein, David Kallend, Karen Smith, James Shepherd, Christopher J. Packard, James Walker, Thomas W. Littlejohn, James W. Blasetto |
|---|---|
| Rok vydání: | 2004 |
| Předmět: |
medicine.medical_specialty
Apolipoprotein B Hormone Replacement Therapy Lipoproteins medicine.medical_treatment Hypercholesterolemia Administration Oral Blood lipids Placebo Placebos Double-Blind Method Internal medicine medicine Humans Rosuvastatin Rosuvastatin Calcium Aged Sulfonamides Dose-Response Relationship Drug biology business.industry nutritional and metabolic diseases Hormone replacement therapy (menopause) General Medicine Middle Aged Fluorobenzenes Postmenopause Regimen Dose–response relationship Pyrimidines Endocrinology biology.protein Female lipids (amino acids peptides and proteins) business medicine.drug |
| Zdroj: | Current Medical Research and Opinion. 20:1571-1578 |
| ISSN: | 1473-4877 0300-7995 |
| DOI: | 10.1185/030079904x4167 |
| Popis: | To evaluate the efficacy and safety of rosuvastatin in postmenopausal women with hypercholesterolemia who are receiving hormone replacement therapy (HRT) in a randomized, double-blind, placebo-controlled trial.After a 6-week dietary lead-in period, 135 postmenopausal women who had been taking a stable HRT regimen for at least 3 months were randomized to receive rosuvastatin 5 mg, 10 mg or placebo for 12 weeks. Fasting levels of low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), total cholesterol (TC), and triglycerides (TG) were assessed at weeks 0, 2, 6, 10, and 12; apolipoprotein (Apo) B and Apo A-I were measured at weeks 0 and 12.Rosuvastatin 5 mg and 10 mg significantly reduced LDL-C by 38% (SE = 2.1) and 49% (SE = 2.1), respectively, compared with placebo (1% [SE = 2.1]; p0.001). TC, TG, Apo B, and all lipid ratios examined (LDL-C/HDL-C, TC/HDL-C, non-HDL-C/HDL-C, and Apo B/Apo A-I) were also reduced significantly by both rosuvastatin doses (p0.001). HDL-C levels increased significantly in the rosuvastatin groups (11% and 8% for 5 mg and 10 mg, respectively, vs. -0.5% for placebo; p0.001), as did Apo A-I levels (p0.05). The combination of rosuvastatin plus HRT was well tolerated with no apparent differences among treatments in the numbers or types of adverse events reported.Rosuvastatin 5 mg or 10 mg once daily is a well-tolerated and highly efficacious lipid-lowering therapy in postmenopausal women receiving HRT. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|